<DOC>
	<DOCNO>NCT02801682</DOCNO>
	<brief_summary>Invasive Candida infection serious complication immunocompromised patient include undergoing treatment cancer occur also patient treat ICUs . Survival rate invasive candidiasis associate early initiation antifungal therapy ( 15 % mortality rate candidemic patient antifungal therapy day 0 related culture date first blood sample positive yeast compare 41 % patient receive antifungal therapy day 3 ) . Up date , laboratory method clinical decision rule available correct anticipation invasive candidiasis would avoid delay appropriate antifungal therapy initiation . In clinical practice culture base method ( e.g . blood culture ) miss 50 % invasive candidiasis case . Preemptive antifungal therapy therefore often initiate critically ill patient Candida isolate various non-sterile patient sample even without sufficient evidence invasive candidiasis . The disadvantage approach include over- undertreatment patient ( 50 % candidemia case miss , hand 89 % patient treat unnecessarily ) , increase selective pressure development antifungal resistance , potential risk adverse drug reaction , increase cost ( expense antifungal therapy account half antimicrobial medication budget tertiary care hospital ) . In addition , survival benefit could demonstrate strategy ICU patient . The aim study identify biological marker anticipate support diagnosis invasive candidiasis ICU patient , overcome current deficiency detection invasive candidiasis consequently differentiate Candida spp . colonization invasive Candida infection . The investigator intend examine time dependent course potential host pathogen derive biomarkers well innate acquire predisposition invasive candidiasis ; e.g . automate ( 1→3 ) ß- D- Glucan test , DNA serum blood sample , pathogen recognition receptor serum marker like interleukin ( IL ) -1 , IL-2 , IL-6 , IL-10 , IL-12 , IL-17A , IL-17F , IL-22 , IL-23 , Tryptophan , Kynurenine , composition indigenous microbiota gastrointestinal low respiratory tract skin , risk factor invasive candidiasis like underlie disease treatment . The study contribute improve assessment ICU patient risk invasive candidiasis improve diagnosis invasive candidiasis ICU patient . In clinical practice reliable differentiation infection colonization allow targeted antifungal therapy lead enhanced antifungal treatment initiation one hand ( case true invasive candidiasis ) reduction unnecessary antifungal treatment treatment cost hand .</brief_summary>
	<brief_title>NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<criteria>ad 1 : subject without evidence current chronic infectious disease Clinical radiological laboratory evidence current infectious disease ( temperature &gt; 38°C , elevate CRP &gt; 5mg/dl , leukocytosis &gt; 11400 , elevate neutrophile ) antifungal therapy within 8 week prior inclusion immunosuppressive therapy ( e.g . glucocorticoid , methotrexate , azathioprin , etc ) active haematooncological disease HIV positivity ad 2 : Inclusion criterion : Patients invasive Candidias/Candida sepsis define recent EORTC/MSG definition . Exclusion criterion : glucocorticoid treatment prednisone equivalent ≥20mg/d inherit neutrophil deficiency absolute neutrophil count ≤500cells/mm3 antifungal therapy within 8 week prior inclusion immunosuppressive therapy ( glucocorticoid prednisone equivalent ≥20mg/d , methotrexate , azathioprin etc ) active hematooncological disease HIV positivity ad 3 : Inclusion criterion : ICU patient sepsis proven bacteremia ( Staph . aureus E. coli ) Exclusion criterion : Antifungal therapy within 8 week prior inclusion immunosuppressive therapy ( glucocorticoid prednisone equivalent ≥20mg/d , methotrexate , azathioprin etc ) active hematooncological disease HIV positivity ad 4 : Inclusion criterion : ICU patient without invasive candidiasis define , without bacteremia without clinical laboratory marker infection ( e.g . intubate mechanically ventilated patient stroke CPR ) Exclusion criterion : Clinical radiological laboratory evidence current infectious disease ( temperature &gt; 38°C , elevate CRP &gt; 5mg/dl , leukocytosis &gt; 11400 , elevate neutrophile ) antifungal therapy within 8 week prior inclusion immunosuppressive therapy ( e.g . glucocorticoid , methotrexate , azathioprin , etc ) active haematooncological disease HIV positivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>